Skip to content


Volume 11 Supplement 1

Challenges in malaria research

  • Poster presentation
  • Open Access

A new therapy for drug-resistant malaria using Plasmodium synthetic lethality inference

  • 1 and
  • 1
Malaria Journal201211 (Suppl 1) :P61

  • Published:


  • Malaria
  • Antimalarial Drug
  • Synthetic Lethal
  • Antimalarial Drug Resistance
  • Target Gene Candidate


If one gene of the Plasmodium (P.) synthetic lethal (SL) gene pair has antimalarial drug resistance (ADR), a drug targeting the other gene of the SL pair can be used as an effective antimalarial drug for treating drug-resistant strains of malaria diseases. The approach introduced in this study is based on bioinformatic database integration. It employs a promising concept of synthetic lethality and has practical applicability in identifying gene targets to discover potential future drugs.

Materials and methods

Potential antimalarial drug target genes were identified by integrating whole biological information from many databases, including BioGRID [1], KEGG SSDD database [2], GeneDB [3], PlasmoDB [4], and Ensembl [5]. The representations of the resulting networks were constructed by using Cytoscape (version 2.8.1) [6]. The distribution networks on gene ontology annotation (GOA) terms were statistically analyzed using BINGO 2.44 Cytoscape plugging [7]. The fitness data on the yeast homologous genes of the finally selected P. genes were searched to find new drugs for clinical malaria treatment from Yeast Fitness DB [8].


A simple computational tool to analyze inferred SL genes of P. species (P. falciparum, P. vivax and P. berghei) was established to identify SL genes that are possible drug targets. Information on SL gene pairs with ADR genes and their first neighbors from the yeast SL gene was inferred to search for pertinent antimalarial drug targets. We suggested that specific antimalarial drug candidates can be inferred by searching drugs that cause a fitness defect in the yeast SL gene.


We suggest a new concept of drug-resistant malaria therapy in this study. The alternative antimalarial drug therapy consists of data integration and inference through the homology analysis of yeast-human-P. Malaria parasites can be killed by mutating or blocking the SL partner of ADR genes. This concept is useful in selecting candidates as drug targets in antimalarial therapy. The methodology also provides not only drug target gene candidates for further experimental validation, but also information on new usage for already-described drugs. Drug candidates for targeting the suggested genes significantly benefit experimental validation in antimalarial drug discovery.



This research was supported by the World Class University program of the National Research Foundation (NRF) of Korea, and funded by the Ministry of Education, Science, and Technology (MEST; R31-2008-000-10105-0 or R31-10105) as well as the Creative Research Initiatives (Center for Biofluid and Biomimic Research) of the MEST and NRF of Korea.

Authors’ Affiliations

Center for Biofluid and Biomimic Research, Division of Integrative Biosciences and Biotechnology, Pohang University of Science and Technology (POSTECH), San 31, Hyoja Dong, Namgu, Pohang, 790-784, Korea


  1. BioGRID (Biological General Repository for Interaction Datasets). []
  2. KEGG SSDD database (Kyoto Encyclopedia of Genes and Genomes). []
  3. GeneDB. []
  4. PlasmoDB. []
  5. Ensembl. []
  6. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T: Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003, 13 (11): 2498-2504. 10.1101/gr.1239303.PubMed CentralView ArticlePubMedGoogle Scholar
  7. Maere S, Heymans K, Kuiper M: Bingo: a cytoscape plugging to assess over-representation of gene ontology categories in biological networks. Bioinformatics. 2005, 21 (16): 3448-3449. 10.1093/bioinformatics/bti551.View ArticlePubMedGoogle Scholar
  8. FitDB. []


© Seo and Lee; licensee BioMed Central Ltd. 2012

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate. Please note that comments may be removed without notice if they are flagged by another user or do not comply with our community guidelines.